Genitourinary Medical Oncology
Milano
Via Giacomo Venezian, 1 , 20133 Milano MI
The Department of Genitourinary Medical Oncology is dedicated to the diagnosis and treatment of cancers of the male urinary and genital systems: prostate, kidney, urothelium (bladder and upper urinary tract), adrenal cortex and germ cell tumours.
We work in multidisciplinary teams comprising oncologists, urologists, radiotherapists, radiologists, nuclear medicine specialists and pathologists, to offer each patient a comprehensive and personalised treatment pathway.
Treatments follow internal quality protocols (PDTA), which are regularly updated and based on the most important international guidelines (AIOM, ESMO, ASCO, EAU, AUA, NCCN).
Our aim is to ensure care that meets the most advanced standards and to offer access to innovative therapies through participation in national and international clinical trials, always adopting an approach that prioritises quality of life and ethical standards in research.
Clinical activity focuses both on the early stages of the disease (adjuvant treatments and those integrated with surgery) and on the management of advanced forms, predominantly on an outpatient basis, with the option of hospital admission for complex therapies or the management of complications.
Research is an essential part of our mission.
We are actively involved in the development of new medicines and in translational research, with the aim of improving existing treatments and gaining a better understanding of rare cancers and the mechanisms of drug resistance. We support independent, non-profit clinical trials funded by organisations such as AIRC, the Ministry of Health and the European Union, and we are strongly committed to translational research in an effort to bring discoveries from the laboratory to the patient’s bedside.
The outpatient clinics of the SSD Genitourinary Medical Oncology Unit take place from Monday to Friday, between 8:30 a.m. and 5:00 p.m., on the 2nd floor of Block E.
First visits: Monday morning and Friday morning (depending on the specific conditions)
Follow-up visits: available every day, Monday through Friday
Telemedicine visits: Thursday
Medical staff may carry out private practice activities within the hospital (intramoenia), in accordance with the internal regulations.
Outpatient visits, both under the National Health Service (SSN) and in private practice, can be booked through the Institute’s General Outpatient CUP (Central Booking Office).
The Department of Genitourinary Medical Oncology specialises in the diagnosis and treatment of malignant tumours of the male urinary and genital systems.
Treatment plans are developed through multidisciplinary collaboration with radiotherapists, urologists, radiologists, nuclear medicine specialists and pathologists, to offer each patient a personalised treatment pathway and access to innovative therapies.
Prostate cancer: this is a very common condition, particularly in older men.
Early diagnosis allows for a watch-and-wait approach in low-risk cases, which can benefit from a ‘watch-and-wait’ strategy whilst preserving quality of life; meanwhile, for patients with advanced forms of the disease, new-generation hormonal therapies, chemotherapy, molecularly targeted drugs (e.g. PARP inhibitors) and innovative radiotherapies (radium and lutetium-PSMA), with a significant impact in terms of improved survival and quality of life.
Kidney cancer: a condition with a low incidence in the general population, accounting for around 2% of all cancers, which requires a high level of specialisation for appropriate clinical management.
Over the last decade, new drugs, such as tyrosine kinase inhibitors and immunotherapy, and strategies combining these, have significantly improved the prognosis.
Urothelial cancer: very common, particularly in low-grade forms. It is managed in close collaboration with urologists to provide integrated treatments aimed at preserving the organ.
Germ cell tumours: these mainly affect young people and require careful management for early detection and treatment of relapses, surgical preservation of the organ and fertility, with a focus on long-term follow-up.
Adrenocortical tumour: a very rare tumour requiring integrated management by expert oncologists and endocrinologists. Clinical research is opening up new therapeutic prospects.
- Mail: programmaprostata@istitutotumori.mi.it
- Tel: 0223903033
- Tel: 0223902122
Monday to Friday from 9:00 a.m. to 6:00 p.m.
Access hours for medical representatives: by appointment, to be arranged with the Secretariat
Dott. Procopio Giuseppe
Direttore struttura
Dott.ssa Verzoni Elena
Medical Director
Dott.ssa Claps Mélanie
Medical Director
Dott.ssa Guadalupi Valentina
Medical Director
Dott.ssa Giannatempo Patrizia
Medical Director
Dott. Stellato Marco
Medical Director
Dott. Nuzzo Amedeo
Medical Director
Dott. Zimatore Matteo
Medical Director
Dott. Rametta Alessandro
Medical Director
Specializzandi:
Noemi Crippa
Mattia Di Civita
Eleonora Gusmaroli
Federica Mascaro
Simone Rota
Infermiera di ricerca:
Chiara Vela
Arianna Sparamonti
Ricercatori sanitari:
Cristina Marenghi
Segreteria:
Antonella Candosin
Carla Ghisani
Supporto alla rierca
Project Manager:
Elena Bertocchi
Francesca Vergani
Case Manager:
Carmen Di Ruocco
Data Manager – Study Coordinator (per patologia genitourinaria maschile):
Fabio Badenchini
Annalisa Redaelli
Alice Bonesi
Martina Chiaretti
Martina Ferrari
Silvia Paglia
Michele Sardano
Veronica Vivona
A double-blind randomised phase III trial evaluating the efficacy of ADT +/- darolutamide in de novo metastatic prostate cancer patients with vulnerable functional ability and not elected for docetaxel or androgen recept
A Phase 1/2 Open-Label Rolling-Arm Umbrella Platform Study of Investigational Agents With or Without Pembrolizumab in Participants with PD-1/L1 Refractory Locally Advanced or Metastatic Urothelial Carcinoma (KEYMAKER-U04
A Phase 1/2 Randomized, Umbrella Study to Evaluate the Efficacy and Safety of MK-2870 Plus Enfortumab Vedotin (EV) in Combination With Pembrolizumab, as Treatment for Participants With Advanced Urothelial Carcinoma (KEYM
A Phase 1/2, Open-label Umbrella Substudy of MK-2400-U01 Master Protocol to Evaluate the Safety and Efficacy of Ifinatamab Deruxtecan-based Treatment Combinations or Ifinatamab Deruxtecan Alone in Participants With Metas
A Phase 2 Open-label Randomized Study of V940 in Combination With BCG Versus BCG Monotherapy in Participants With High-risk Non-muscle Invasive Bladder Cancer (INTerpath-011)
A Phase 3 Randomized, Double-blind, Placebo-controlled Study of Pasritamig (JNJ78278343), a T-cell-redirecting Agent Targeting Human Kallikrein 2, + Best SupportiveCare Versus Best Supportive Care for Metastatic Castrati
A Phase 3 Randomized, Open-label Study of MK-5684 Versus Alternative Abiraterone Acetate or Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) Previously Treated With Next-generatio
A Phase 3, Open-label Study of Ifinatamab Deruxtecan Versus Docetaxel in Participants with Metastatic Castration-Resistant Prostate Cancer (mCRPC) (IDeate-Prostate01)
A Phase 3, Open-label, Multicenter, Randomized Study of Xaluritamig Plus Abiraterone Versus Investigator’s Choice in Participants with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer
A Phase 3, Randomized, Open-label Study of Belzutifan + Zanzalintinib Versus Cabozantinib in Participants with Advanced RCC who Experienced Disease Recurrence During or After Prior Adjuvant Anti-PD-1/L1 Therapy (LITESPAR
A Phase 3, Randomized, Open-label Study of Sacituzumab Tirumotecan (MK-2870) Versus Investigator’s Choice of Non-platinum Chemotherapy in Participants with Pretreated Locally Advanced/Metastatic Urothelial Carcinoma
A Phase 3, Two-part, Randomized, Open-label, Adaptive Study Comparing BMS-986365 versus Investigator’s Choice of Therapy Comprising Either Docetaxel or Second Androgen Receptor Pathway Inhibitor (ARPI), in Participants w
A phase Ib/II open-label, multi-center study of the DNA protein kinase inhibitor AMO959 with lutetium (177Lu) vipivotide tetraxetan (AAA617) in combination with an androgen receptor pathway inhibitor (ARPI) in adult part
A Randomised, Double-blind, Placebo-controlled, Phase III Study of Adjuvant Saruparib (AZD5305) in Patients with BRCAm Localised High-Risk Prostate Cancer Receiving Radiotherapy with Androgen Deprivation Therapy (EvoPAR-
A Randomized, Double-Blind, Active-Control, Multicenter Phase 3 Trial of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma
A two part, Phase 1 dose escalation and expansion followed by randomized Phase 2, multicenter, study to assess the safety and efficacy of the combination of tulmimetostat (DZR123) and JSB462 (ARV-766) vs standard of care
Activity of Pembrolizumab plus Enfortumab Vedotin in Collecting Duct and Renal Medullary Carcinoma (REPRINT Study)
CARE1: A first-line, randomized platform study to optimize treatment in patients with metastatic renal cell carcinoma.
MRI Imaging for Active Surveillance in Prostate Cancer
Last update: 04/05/2026